



MYDECINE[™]
M E D I C I N E E V O L V E D

March 2022*

Mydecine Innovations Group

(CSE:MYCO) (AQSE:MYIG)

(OTC:MYCOF) (FSE:0NFA)

Disclaimer

General

The information provided in this presentation pertaining to Mydecine Innovations Group Inc. ("Mydecine" or the "Company"), its business assets, strategy and operations is for general informational purposes only and is not a formal offer to sell or a solicitation of an offer to buy any securities, options, futures or other derivatives related to securities in any jurisdiction and its content is not prescribed by securities laws. Information contained in this presentation should not be relied upon as advice to buy or sell or hold such securities or as an offer to sell such securities. This presentation does not take into account nor does it provide any tax, legal or investment advice or opinion regarding the specific investment objectives or financial situation of any person. While the information in this presentation is believed to be accurate and reliable, Mydecine and its agents, advisors, directors, officers, employees and shareholders make no representation or warranties, expressed or implied, as to the accuracy of such information and Mydecine expressly disclaims any and all liability that may be based on such information or errors or omissions thereof.

Mydecine reserves the right to amend or replace the information contained herein, in part or entirely, at any time, and undertakes no obligation to provide the recipient with access to the amended information or to notify the recipient thereof. The information contained in this presentation is intended only for the persons to whom it is transmitted for the purposes of evaluating the Company. The information contained in this presentation supersedes any prior presentation or conversation concerning the Company. Any information, representations or statements not contained herein shall not be relied upon for any purpose. Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this presentation by you or any of your representatives or for omissions from the information in this presentation. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by third parties in respect of the matters discussed in this presentation.

Confidentiality

This presentation is confidential and is intended, among other things, to present a general outline of the Company. The contents are not to be reproduced or distributed to the public or press. Each person who has received a copy of this presentation (whether or not such person purchases any securities) is deemed to have agreed: (i) not to reproduce or distribute this presentation, in whole or in part, without the prior written consent of the Company, other than to legal, tax, financial and other advisors on a need to know basis, (ii) if such person has not purchased securities, to return this presentation to the Company upon its request (iii) without the prior written consent of the Company, not to disclose any information contained in this presentation except to the extent that such information was (a) previously known by such person through a source (other than the Company) not bound by any obligation to keep such information confidential, (b) in the public domain through no fault of such person, or (c) lawfully obtained at a later date by such person from sources (other than the Company) not bound by any obligation to keep such information confidential, and (iv) to be responsible for any disclosure of this presentation, or the information contained herein, by such person or any of its employees, agents or representatives.

Forward-Looking Statements

Certain information set forth in this presentation contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company's business, projects and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company's current customer, supplier and other material agreements; and (viii) future liquidity, working capital and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

About Mydecine



Mydecine is a biotechnology company developing innovative first- and second-generation novel therapeutics to treat mental health and addiction disorders through our world-class technology and drug development infrastructure. Our team has extensive experience in drug development, medicinal chemistry, clinical trials, mental health and addiction disorders.





Executive Summary



Global Partnerships

- Exclusive partnership with Applied Pharmaceutical Innovations working out of the University of Alberta
- Strategic partners with leading psychedelic research center Johns Hopkins University
- Strong relationships with academic organizations advancing psychedelic research

IP and Drug Development

- Global team with extensive experience in medicinal chemistry, pharmaceutical drug development, regulatory and IP strategy
- Developing novel molecules tailored for medical use with improved efficacy, controllability, delivery mechanisms and safety
- Layered approach to patent strategy maximizing protection and increasing value

Clinical Trials

- Only industry sponsored clinical trial assessing psilocybin-assisted therapy as a smoking cessation treatment
- Phase 2 clinical trial assessing psilocybin-assisted therapy for the treatment of PTSD in veterans
- Working closely with internationally recognized consulting firms ProPharma Group and Ethica CRO

Technology

- Utilizing advanced artificial intelligence and machine learning to design and screen drugs of interest

Our Mission & Vision




Mission



Our mission is to become a trusted source of safe and effective medication-based treatments to address the unmet needs for mental health and addiction disorders.

Vision




Through technology and research, our vision is to become the number one globally trusted leader in the treatment of mental health and addiction disorders. We see success when all medical and therapy communities view psychedelic medicine as an accepted and adopted form of treatment offered in our existing healthcare infrastructure.

Our Approach



IP & Drug Development




Clinical Trials



Technology



IP & Drug Development




Lead Drug Candidates



MYDECINE™
MEDICINE EVOLVED

MEDICINE EVOLVED



Lead Drug Candidates - - - - -




MYCO - 004
Patch-delivered
tryptamine compound

- Skin permeable and patch delivered
- Two-hour duration
- Faster onset time
- Reduced side effects
- Multiple layers of patent protection
- Better suited for existing healthcare infrastructure



MYCO - 005
Family of improved
psilocin analogs

- Increased safety and stability profile
- Strong binding at 5-HT2A receptor
- Non-binding at 5-HT2B receptor (potentially heart safe)
- Faster onset time
- Strong potential to pair with skin permeable feature set



MYCO - 006
Family of short-acting
MDMA analogs

- Increased safety and stability profile
- 1-2 hour duration
- More scalable treatment with shorter half-life
- Reduced cost of treatment by decreasing total treatment time
- Better suited for existing healthcare infrastructure



Artificial Intelligence Drug Discovery Program



- Through our exclusive partnership with Applied Pharmaceutical Innovation and the University of Alberta, we are utilizing artificial intelligence and machine learning (AI/ML) to design and screen our drugs of interest
- The University of Alberta is ranked top 3 globally for AI research and considered Canada's #1 Computing Science Department
- Our program is led by top computer-aided drug development expert, Dr. Khaled Barakat, in conjunction with researchers at the University of Alberta
- Through AI/ML we are able to screen billions of compounds rapidly without the need to produce them and immediately collect data on viable drug candidates prior to further investment in development
- Our program combines AI with in-silico structural modeling to design novel serotonin receptor modulators and assess drugs around these receptors
- We have completed a target-based model of the classic psychedelic serotonin receptor 5-HT_{2A} and will continue to build receptor models to include the complete family of serotonin receptors

Clinical Trials

THE
Newly
INSTITUTE




Clinical Trial Highlights



Johns Hopkins University is the lead investigator for two concurrently running MYCO-001 smoking cessation studies launching in 2022

001



Mydecine is the only biotech company targeting smoking cessation as an indication

001



Our industry sponsored smoking cessation study builds off Dr. Matthew Johnson's ongoing research showing an 80% efficacy rate at six months


001



Investigator initiated MYCO-001 multi-site proof of concept PTSD study targeting the veteran population set to launch in 2022



Addiction Crisis and Growing Market Opportunity



• In the U.S., tobacco kills more than AIDS, alcohol, car accidents, illegal drugs, murders and suicides combined



• 68% of smokers would like to quit but only 7.5% are successful



• \$64 billion increase in global smoking cessation market by 2026



• \$1.1 billion opportunity after Chantix recall in 2021

https://www.cdc.gov/tobacco/data_statistics/fact_sheets/fast_facts/index.htm#:~:text=Cigarette%20smoking%20is%20responsible%20for,or%201%2C300%20deaths%20every%20day.&text=On%20average%2C%20smokers%20die%2010%20years%20earlier%20than%20nonsmokers.

https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm
<https://www.tobaccofreekids.org/problem/toll-us>

<https://www.businesswire.com/news/home/20200319005381/en/Global-Smoking-Cessation-Market---Expected-to-Reach-63.99-Billion-by-2026-Growing-at-a-CAGR-of-16.9---ResearchAndMarkets.com>

<https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-nitrosamine-varenicline-chantix>

<https://www.fiercepharma.com/pharma/endo-s-smoking-cessation-generic-rushed-over-fda-s-finish-line-effort-to-fill-chantix>



Positive Clinical Data Assessing Psilocybin for Smoking Cessation



● 2016 Smoking Cessation Study



- 15 participants
- Psilocybin + cognitive behavioral therapy (CBT) (3 doses)
- 12 month follow-up
- 67% abstinence from smoking



● 2022 Smoking Cessation Study



- 100 participants
- Psilocybin + cognitive behavioral therapy (CBT) (1 dose)
Nicotine Replacement Therapy + CBT
- 12 month follow-up
- 59% abstinence from smoking
28% abstinence from smoking



MYCO-001 Smoking Cessation Studies



Industry Sponsored Phase 2b Clinical Trial

- First industry sponsored trial assessing psilocybin for smoking cessation
- Flagship site at Johns Hopkins University
- Anticipated launch Q2 2022
- MYCO-001 (single dose) + CBT vs placebo



Investigator Initiated NIDA Grant-Funded Clinical Trial

- 1st time in 50 years that the US Federal Government has funded the study of psychedelics for therapeutic use
- Johns Hopkins University, New York University, University of Alabama Birmingham
- Anticipated launch Q2 2022
- MYCO-001 (2 doses) + CBT vs placebo
- NIDA - National Institute on Drug Abuse



MYCO-001 - for Smoking Cessation




Candidate: MYCO-001, 99% pure psilocybin

Indication: Smoking Cessation

TWO CLINICAL TRIALS

1. Industry Sponsored Phase 2b Clinical Trial
2. Investigator Initiated NIDA Grant-Funded Study

Research: Led by Dr. Matthew Johnson, Ph.D.





MYCO-004 - for Smoking Cessation




Candidate: MYCO-004, tryptamine compound patch-delivered

Indication: Substance Use Disorder and Smoking Cessation

Preclinical / IND-enabling studies

Research: To Be Announced



PTSD Crisis and Growing Market Opportunity



- Almost 8 million people in the US have PTSD
- 30% of combat veterans will develop PTSD
50% of combat veterans do not respond to current treatments
- \$990 million PTSD treatment global market in 2021
- Currently there are no FDA-approved drugs developed to treat PTSD



MYCO-001 - for PTSD



Candidate: MYCO-001, 99% pure psilocybin

Indication: PTSD in veterans, emergency medical service (EMS) and front-line workers

Proof of Concept Study

Research: Led by Dr. Eric Vermetten



- ★ Completed investigator's brochure
- ★ Completed draft protocol and submitted to IRB for efficacy review
- IRB approval
- IND submission
- Patient recruitment
- First patient dosed



----- Programs, Partnerships and Leadership-Team -----





Global Partnerships



- Through our exclusive partnership with API, we have access to a world-class, end-to-end drug development infrastructure at the University of Alberta led by a highly experienced team all under one roof.
- University of Alberta's Faculty of Pharmacology is currently ranked in the top 15 in the world for pharmaceutical drug discovery. Their artificial intelligence program is ranked top 3 in the US and Canada.




- We have partnered with Johns Hopkins University (JHU) to advance our clinical trial and research initiatives.
- JHU is considered the top university for psychedelic research globally and will act as the the flagship site for two MYCO-001 smoking cessation studies launching in 2022. Dr. Matthew Johnson will act as the principal investigator for both concurrently running studies.
- We have entered into a separate 5-year master collaboration research agreement to research multiple molecules for a variety of indications.



- Through our partnerships with Ethica CRO and ProPharma Group, we have enhanced our protocols and clinical trial development while streamlining procedures to increase efficiencies and reduce risk.
- We have been working closely with these internationally recognized consulting firms to ensure all regulatory requirements are met or exceeded.




Sponsored Research




Sponsored psilocybin study led by Principal Investigator Dr. Jaylyn Waddell. Intriguing potential insight into the mechanism of psilocybin and provides a roadmap for biomarker discovery.

**Imperial College
London**




Microdosing study led by Principal Investigator Dr. David Erritzoe. Creation of a novel collaborative psychopharmacology/psychedelic research clinic between ICL and a major mental health NHS Trust in London.



Sponsored psilocybin study led by Principal Investigator Dr. Jaylyn Waddell. Intriguing potential insight into the mechanism of psilocybin and provides a roadmap for biomarker discovery.

Special Access Support and Supply Program

- Healthcare providers can now apply for psilocybin and MDMA to treat qualified patients through Health Canada's Special Access Program (SAP)
- We have launched the Special Access Support and Supply Program (SASSP)
- Through our program we can offer support to clinics and physicians looking to treat patients with psilocybin and MDMA in Canada
- Our program aims to promote safe and effective therapy outcomes, create long-term relationships with clinics and hospitals and expand patient access to treatments while creating near-term revenue for shareholders
- SASSP is a package of goods and services including cGMP psilocybin and MDMA, training and advisory services, investigative brochures, protocols, therapy manuals and personalized patient support





Investor Relations Contact

corp@mydecineinc.com

T: 604-687-2038



Canada Office

Suite 810–789 West
Pender Street,
Vancouver, British
Columbia, V6C 1H2



@mydecineig



@mydecine



Mydecine innovations group

Appendix



2021 Milestones

★ Completed ● Anticipated



Sponsored lab based study of established microdosers

Uplisted to the NEO exchange

Announced MYCO-001 seamless phase 2/3 smoking cessation trial

Sponsors study of neuron level response of University of Maryland

Announced partnership with LeadGens Labs

Filed new patent application for MDMA-like compound

Launched AI-driven drug discovery program

Filed patent application covering new formulations that bring nanoemulsion technology to traditional medicine ingredients

Q1 2021

Q2 2021

Q3 2021

Q4 2021

Filed application to list on the NASDAQ

Announced four lead novel drug candidates

Filed MYCO-003 final patent application and reported positive preclinical data

Announced plan to supply MYCO-001 for NIDA grant funded smoking cessation study

Completed first ever international export of psilocybin mushrooms

Discovered over 40 pharmacologically active compounds in mushrooms

Announced five-year collaborative research agreement with Johns Hopkins University